yuanyuan ma

Prof. yuanyuan ma


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Theranostics
Verified
Journal Article
Open access
PZPanpan Zhang
Panpan Zhang
SLShaolei Li
Shaolei Li
CLChao Lv
Chao Lv
JSJiahui Si
Jiahui Si
YXYing Xiong
Ying Xiong
YYYue Yang
Yue Yang
Activation of c-Met plays a critical role in tumorigenesis, migration and invasion in lung cancer. Here, we explored the therapeutic efficacy of a novel small-molecule c-Met inhibitor (BPI-9016M) in lung adenocarcinoma and investigated the underlying molecular mechanisms.

1 January 2022 in Journal of Cancer
Verified
Journal Article
Open access
CDChenyue Dai
Chenyue Dai
ZMZeming Ma
Zeming Ma
JSJiahui Si
Jiahui Si
GAGuo An
Guo An
WZWenlong Zhang
Wenlong Zhang
YMyuanyuan ma
yuanyuan ma
Purposes: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used for patients with gefitinib (first-generation EGFR-TKI) resistance, but osimertinib resistance inevitably occurs. Therefore, it is necessary to explore the mechanisms of osimertinib resistance.

1 January 2022 in Journal of Cancer
Verified
Journal Article
Open access
YHYang Hong
Yang Hong
JSJiahui Si
Jiahui Si
BXBufan Xiao
Bufan Xiao
YXYing Xiong
Ying Xiong
CDChenyue Dai
Chenyue Dai
YMyuanyuan ma
yuanyuan ma
Purpose: Due to the high metastatic ability and poor prognosis of lung adenocarcinoma (LUAD), we identified novel non-coding RNAs, which constitute approximately 60% of human transcripts, as prognostic biomarkers and potential therapeutic targets for LUAD.

1 January 2021 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
PDF file
CDChenyue Dai
Chenyue Dai
BLBing Liu
Bing Liu
SLShaolei Li
Shaolei Li
YHYang Hong
Yang Hong
JSJiahui Si
Jiahui Si
YMyuanyuan ma
yuanyuan ma
Objectives: Epidermal growth factor receptor-tyrosine kinase inhibitors are widely used for lung epidermal growth factor receptor-positive lung adenocarcinomas, but acquired resistance is inevitable. Although non-coding RNAs, such as circular RNA and microRNA, are known to play vital roles in epidermal growth factor receptor-tyrosine kinase inhibitor resistance, comprehensive analysis is lacking. Thus, this study aimed to explore the circular RNA-microRNA-messenger RNA regulatory network involved in epidermal growth factor receptor-tyrosine kinase inhibitor resistance. Methods: To identify differentially expressed genes between the epidermal growth factor receptor-tyrosine kinase inhibitor sensitive cell line PC9 and resistant cell line PC9/ epidermal growth factor receptor-tyrosine kinase inhibitor resistance(PC9/ER), circular RNA, microRNA and messenger RNA microarrays were performed. Candidates were then identified to construct a circular RNA-microRNA-messenger RNA network using bioinformatics. Additionally, Gene Oncology and Kyoto Encyclopedia of Genes and Genomes pathway analyses were conducted to evaluate the network messenger RNA, setting up a protein-protein interaction network for hub-gene identification. Afterwards, RNA immunoprecipitation was performed to enrich microRNA, and quantitative real-time PCR was used to estimated gene expression levels. Results: In total, 603, 377, and 1863 differentially expressed circular RNA, microRNA, messenger RNAs, respectively, were identified using microarray analysis, constructing a circular RNA-microRNA-messenger RNA network containing 18 circular RNAs, 17 microRNAs and 175 messenger RNAs. Moreover, Gene Oncology and Kyoto Encyclopedia of Genes and Genomes pathway analyses showed that the most enriched biological process terms and pathways were related to epidermal growth factor receptor-tyrosine kinase inhibitor resistance, including Wnt and Hippo signaling pathways. Based on the competing endogenous RNA and protein-protein interaction network, circ-0007312 was showed to interact with miR-764 and both circ-0003748 and circ-0001398 were shown to interact with miR-628; both these microRNAs targeted MAPK1. Furthermore, circ-0007312, circ-0003748, circ-0001398, and MAPK1 were up-regulated, whereas miR-764 and miR-628 were downregulated in PC9/ER cells as compared to parental PC9 cells. We also found that circ-0007312 and miR-764 were positively expressed in plasma. Conclusions: Our original study associated with mechanism of target therapy in lung cancer provided a systematic and comprehensive regulation of circular RNA, microRNA and messenger RNA in epidermal growth factor receptor-tyrosine kinase inhibitor resistance. It was found that circ-0007312- miR-764-MAPK1, circ-0003748-miR-628-MAPK1, and circ-0001398-miR-628-MAPK1 axis may play key roles in epidermal growth factor receptor-tyrosine kinase inhibitor resistance.

3 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
YHYang Hong
Yang Hong
JSJiahui Si
Jiahui Si
JZJie Zhang
Jie Zhang
YXYing Xiong
Ying Xiong
JZJianzhi Zhang
Jianzhi Zhang
YMyuanyuan ma
yuanyuan ma
Objective: The size distribution of circulating aneuploid cells (CACs) and its clinical significance were investigated in resectable non-small cell lung cancer (NSCLC).Patients and Methods: A total of 50 patients with resectable NSCLC were enrolled in this study. Blood samples (50 pre-surgery and 35 post-surgery) were collected and used for the detection of CAC chromosome 8 heteroploidy through the subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH) method.Results: Less than 20% small cell size and more than 80% large cell size CACs were detected. Karyotypes, including triploid, tetraploid, and multiploid, had varying distributions. The triploid subtype accounted for the majority of small cell size CACs, whereas the multiploid subtype accounted for the majority of large cell size CACs. We found that total small cell size and triploid small cell size CACs, but not large cell size CACs, derived from pre-surgery samples, were associated with shorter disease-free survival. Moreover, total small cell size and triploid small cell size CACs were associated with higher TNM stage and recurrence. Nevertheless, the variation between pre- and post-surgery CACs was not related to survival among patients with resectable NSCLC.Conclusions: Pre-surgery small cell size CACs, especially the triploid subtype, could be regarded as a potential prognostic biomarker for patients with resectable NSCLC.

31 March 2012 in Journal of Solid Tumors
Verified
Journal Article
Open access
PDF file
XLXiao-Feng Li
Xiao-Feng Li
YMyuanyuan ma
yuanyuan ma
HJHuijie Jiang
Huijie Jiang
Most cancer-related deaths are due to the development of metastatic disease rather than the growth of primary tumors. Adjuvant treatment often does not translate into substantial improvements in overall survival; subclinical micro-metastases may be resistant to multiple therapies. Understanding microenvironment factors such as hypoxia, proliferation and glucose metabolism in micro-metastases is of importance for micro-metastases treatment; hypoxia, commonly observed in most primary solid malignancies, is associated with tumor progression, increased aggressiveness, enhanced metastatic potential and poor prognosis and hypoxic tumor cells are more resistant to radiotherapy and some forms of chemotherapy. In this article, we discussed hypoxia status of micro-metastases, and related this to cellular proliferation and glucose metabolism. We also proposed hypoxia as a therapeutic target for micro-metastases.